{
  "disease_name": "Melanoma",
  "synonyms": [
    "Malignant melanoma",
    "Cutaneous melanoma",
    "Skin melanoma"
  ],
  "summary": "Melanoma is a malignant tumor arising from melanocytes, the pigment-producing cells of the skin. It is the most dangerous form of skin cancer due to its high potential for metastasis. While most cases originate in the skin, melanoma can also occur in mucosal surfaces, the eye, and rarely internal organs.",
  "causes": [
    "Ultraviolet (UV) radiation exposure from sunlight or tanning beds",
    "DNA damage from UV-induced thymine dimers",
    "Genetic mutations in BRAF, NRAS, NF1, and CDKN2A genes",
    "Inherited syndromes such as familial atypical multiple mole melanoma (FAMMM)",
    "Weakened immune system",
    "Xeroderma pigmentosum and DNA repair defects"
  ],
  "risk_factors": [
    "Fair skin and light hair",
    "Excessive UV exposure",
    "History of severe sunburns",
    "Multiple or atypical moles",
    "Family history of melanoma",
    "Older age",
    "Immunosuppression",
    "Male sex"
  ],
  "symptoms": [
    "New or changing mole",
    "Irregular borders or color variation in moles",
    "Itching or bleeding lesion",
    "Asymmetrical skin lesion",
    "Lump or nodular growth on skin",
    "Metastatic symptoms such as fatigue or weight loss"
  ],
  "diagnosis": [
    "Visual skin examination",
    "Dermoscopy",
    "Skin biopsy (excisional preferred)",
    "Histopathological analysis (Breslow thickness, Clark level)",
    "Sentinel lymph node biopsy",
    "CT, MRI, or PET scan for metastasis",
    "BRAF and PD-L1 testing"
  ],
  "treatments": [
    "Surgical excision (wide local excision or Mohs surgery)",
    "Immunotherapy (pembrolizumab, nivolumab, ipilimumab)",
    "Targeted therapy (BRAF inhibitors like vemurafenib, dabrafenib; MEK inhibitors like trametinib)",
    "Radiation therapy for metastatic lesions",
    "Chemotherapy (dacarbazine, temozolomide)",
    "Oncolytic virotherapy (T-VEC)",
    "Adoptive cell transfer therapy",
    "Adjuvant interferon-alpha"
  ],
  "related_genes": [
    "BRAF",
    "NRAS",
    "NF1",
    "CDKN2A",
    "TP53",
    "MC1R",
    "KIT",
    "MITF"
  ],
  "subtypes": [
    {
      "name": "Superficial spreading melanoma",
      "typical_patients": "Adults; most common type, especially in Caucasians",
      "five_year_survival": "98% (localized disease)",
      "common_treatments": [
        "Surgical excision",
        "Immunotherapy"
      ]
    },
    {
      "name": "Nodular melanoma",
      "typical_patients": "Middle-aged adults; more aggressive and invasive",
      "five_year_survival": "70% (localized disease)",
      "common_treatments": [
        "Surgical excision",
        "Immunotherapy"
      ]
    },
    {
      "name": "Lentigo maligna melanoma",
      "typical_patients": "Older adults with chronic sun exposure (face, neck)",
      "five_year_survival": "90% (localized disease)",
      "common_treatments": [
        "Wide excision",
        "Mohs surgery"
      ]
    },
    {
      "name": "Acral lentiginous melanoma",
      "typical_patients": "Common in darker-skinned populations, occurs on palms, soles, under nails",
      "five_year_survival": "80% (localized disease)",
      "common_treatments": [
        "Surgery",
        "Immunotherapy"
      ]
    },
    {
      "name": "Uveal (ocular) melanoma",
      "typical_patients": "Adults; develops in the eye (uvea)",
      "five_year_survival": "50% (metastatic disease)",
      "common_treatments": [
        "Radiation therapy",
        "Surgery"
      ]
    }
  ],
  "epidemiology": {
    "global_cases_2015": 3100000,
    "global_deaths_2015": 59800,
    "most_common_in": "Fair-skinned populations in Australia, New Zealand, and Northern Europe",
    "five_year_survival_rate": "99% (localized), 65% (regional), 25% (distant metastasis)"
  },
  "relationships": [
    {
      "source": "Melanoma",
      "relation": "has_symptom",
      "target": "New or changing mole"
    },
    {
      "source": "Melanoma",
      "relation": "has_symptom",
      "target": "Itching lesion"
    },
    {
      "source": "Melanoma",
      "relation": "has_risk_factor",
      "target": "UV exposure"
    },
    {
      "source": "Melanoma",
      "relation": "has_risk_factor",
      "target": "Fair skin"
    },
    {
      "source": "Melanoma",
      "relation": "has_risk_factor",
      "target": "Multiple moles"
    },
    {
      "source": "Melanoma",
      "relation": "has_cause",
      "target": "UV radiation"
    },
    {
      "source": "Melanoma",
      "relation": "has_cause",
      "target": "Genetic mutations (BRAF, NRAS)"
    },
    {
      "source": "Melanoma",
      "relation": "associated_gene",
      "target": "BRAF"
    },
    {
      "source": "Melanoma",
      "relation": "associated_gene",
      "target": "NRAS"
    },
    {
      "source": "Melanoma",
      "relation": "associated_gene",
      "target": "CDKN2A"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Immunotherapy"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Targeted therapy"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Surgery"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Radiation therapy"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Oncolytic virotherapy"
    },
    {
      "source": "Superficial spreading melanoma",
      "relation": "subtype_of",
      "target": "Melanoma"
    },
    {
      "source": "Nodular melanoma",
      "relation": "subtype_of",
      "target": "Melanoma"
    },
    {
      "source": "Lentigo maligna melanoma",
      "relation": "subtype_of",
      "target": "Melanoma"
    },
    {
      "source": "Acral lentiginous melanoma",
      "relation": "subtype_of",
      "target": "Melanoma"
    },
    {
      "source": "Uveal melanoma",
      "relation": "subtype_of",
      "target": "Melanoma"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Pembrolizumab"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Vemurafenib"
    },
    {
      "source": "Melanoma",
      "relation": "treated_with",
      "target": "Dabrafenib"
    },
    {
      "source": "Melanoma",
      "relation": "associated_gene",
      "target": "NF1"
    },
    {
      "source": "Melanoma",
      "relation": "associated_gene",
      "target": "MC1R"
    }
  ]
}